Biotechnologies Assets SA (BST.MC)

EUR 0.32

(3.19%)

Long Term Debt Summary of Biotechnologies Assets SA

Biotechnologies Assets SA's latest annual long term debt in 2023 was 5.15 Million EUR , up 63.33% from previous year.
Biotechnologies Assets SA's latest quarterly long term debt in 2023 FY was 5.15 Million EUR , up 63.33% from previous quarter.
Biotechnologies Assets SA reported annual long term debt of 3.15 Million EUR in 2022, up 1.94% from previous year.
Biotechnologies Assets SA reported annual long term debt of 3.09 Million EUR in 2021, up 37.85% from previous year.
Biotechnologies Assets SA reported quarterly long term debt of 5.15 Million EUR for 2023 Q4, up 55.15% from previous quarter.
Biotechnologies Assets SA reported quarterly long term debt of 3.33 Million EUR for 2023 Q1, up 5.7% from previous quarter.

Annual Long Term Debt Chart of Biotechnologies Assets SA (2023 - 2010)

Historical Annual Long Term Debt of Biotechnologies Assets SA (2023 - 2010)

Year	Long Term Debt	Long Term Debt Growth
2023	5.15 Million EUR	63.33%
2022	3.15 Million EUR	1.94%
2021	3.09 Million EUR	37.85%
2020	2.24 Million EUR	-79.26%
2019	10.82 Million EUR	-71.25%
2018	37.66 Million EUR	3542.0%
2017	1.03 Million EUR	0.6%
2016	1.02 Million EUR	-80.33%
2015	5.22 Million EUR	6.96%
2014	4.88 Million EUR	1267.02%
2013	357.47 Thousand EUR	-4.28%
2012	373.46 Thousand EUR	0.0%
2011	- EUR	0.0%
2010	- EUR	0.0%

Year	Long Term Debt	Long Term Debt Growth
2023 Q2	3.17 Million EUR	-4.89%
2023 Q4	5.15 Million EUR	55.15%
2023 Q1	3.33 Million EUR	5.7%
2023 Q3	3.32 Million EUR	4.72%
2023 FY	5.15 Million EUR	63.33%
2022 FY	3.15 Million EUR	1.94%
2022 Q2	3.62 Million EUR	0.0%
2022 Q4	3.15 Million EUR	0.0%
2021 Q2	3.48 Million EUR	0.0%
2021 Q4	3.09 Million EUR	0.0%
2021 FY	3.09 Million EUR	37.85%
2020 FY	2.24 Million EUR	-79.26%
2020 Q2	14.75 Million EUR	0.0%
2020 Q4	2.24 Million EUR	0.0%
2019 FY	10.82 Million EUR	-71.25%
2019 Q4	10.82 Million EUR	0.0%
2019 Q2	13.87 Million EUR	0.0%
2018 FY	37.66 Million EUR	3542.0%
2018 Q4	37.66 Million EUR	0.0%
2018 Q2	13.4 Million EUR	0.0%
2017 Q4	1.03 Million EUR	0.0%
2017 FY	1.03 Million EUR	0.6%
2017 Q2	975.94 Thousand EUR	0.0%
2016 Q2	1.02 Million EUR	0.0%
2016 Q4	1.02 Million EUR	0.0%
2016 FY	1.02 Million EUR	-80.33%
2015 Q4	5.22 Million EUR	0.0%
2015 FY	5.22 Million EUR	6.96%
2015 Q2	5.08 Million EUR	0.0%
2014 Q4	4.88 Million EUR	0.0%
2014 Q2	3.18 Million EUR	0.0%
2014 FY	4.88 Million EUR	1267.02%
2013 Q4	357.47 Thousand EUR	0.0%
2013 FY	357.47 Thousand EUR	-4.28%
2013 Q2	373 Thousand EUR	0.0%
2012 Q2	3.99 Million EUR	0.0%
2012 FY	373.46 Thousand EUR	0.0%
2012 Q4	373.46 Thousand EUR	0.0%
2011 Q4	- EUR	0.0%
2011 Q2	3.51 Million EUR	0.0%
2011 FY	- EUR	0.0%
2010 FY	- EUR	0.0%
2010 Q4	- EUR	0.0%

Peer Long Term Debt Comparison of Biotechnologies Assets SA

Name	Long Term Debt	Long Term Debt Difference
Atrys Health, S.A.	162.72 Million EUR	96.833%
Oryzon Genomics S.A.	3.45 Million EUR	-49.37%
Pharma Mar, S.A.	27.03 Million EUR	80.936%
Laboratorios Farmaceuticos Rovi, S.A.	52.24 Million EUR	90.134%